Pliant Therapeutics reports Q2 loss of $41.2M; initiates Phase 2b IPF trial, expects PSC data Q3 2023

PLIANT THERAPEUTICS, INC.

2023-Q2 EPS reported -$1.37 revenue$1,580,000

Net loss $41.2M vs $29.5M prior year; R&D $33.0M, G&A $14.6M.
Cash, equivalents & short-term investments $555.2M; sufficient into H2 2026.
Initiated Phase 2b BEACON-IPF trial of bexotegrast in IPF (~270 patients, 160/320 mg).
INTEGRIS-PSC Phase 2a 12-week interim data from 40/80/160 mg cohorts expected Q3 2023.
Promoted Dr. Scott Turner to Chief Scientific Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.